Episode
Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus
- Podcast
- HCPLive Podcasts
- Published
- May 28, 2026
- Duration seconds
- 2167
- Processing state
not_requested- Canonical source
- https://audioboom.com/posts/8909089
Actions
POST https://stenobird.com/v1/public/podcasts/hcplive-podcasts-19526/episodes/joint-ventures-the-b-cell-story-part-2-ianalumab-and-the-next-chapter-in-sj-gren-s-and-lupus/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hcplive-podcasts-19526/joint-ventures-the-b-cell-story-part-2-ianalumab-and-the-next-chapter-in-sj-gren-s-and-lupus.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In the second part of this Joint Ventures episode on B cell therapies in rheumatic disease, hosts Jack Arnold, MBBS, PhD, and Rihards Buss, MD, return with guest Lucy Carter, MBBS, PhD, to move beyond the question of how to deplete B cells and toward the more conceptually challenging problem of what happens after depletion — and whether ianalumab's dual mechanism of action represents the most rational answer yet developed. The episode examines the biologic rationale behind combining rituximab with belimumab, reviews the landmark NEPTUNUS Sjögren disease trials in which ianalumab became the first targeted therapy to meet a phase 3 primary endpoint in the disease, and discusses how emerging therapies may ultimately reshape treatment selection, steroid reduction strategies, and long-term management of autoimmune conditions including Sjögren disease and systemic lupus erythematosus.